Direct answer: Prostate-specific antigen (PSA) is a protein made by prostate cells. A PSA blood test can support an informed prostate-cancer screening decision, help evaluate certain prostate or urinary concerns, and monitor people after prostate-cancer treatment. A high PSA does not prove that cancer is present, and a low PSA cannot completely rule it out. Benign prostate enlargement, inflammation, infection, recent ejaculation, cycling, prostate procedures, medications, age, and prostate size can all affect interpretation. The most useful next step is determined by why the test was ordered, earlier results, symptoms, risk factors, preparation, and whether an unexpected result persists when repeated.[1]
For a broader foundation, use The Complete Guide to Lab Tests and Blood Work to understand test selection, specimens, screening, and monitoring. Review How to Read and Understand Your Lab Results for guidance on reference intervals, flags, units, variation, and trends. Before ordering, preparing, or following up, see Direct-Access Lab Testing: How It Works and What to Expect.
This article supports the Men's Health Blood Tests pillar and the Cancer Blood Tests and Tumor Markers pillar.
PSA stands for prostate-specific antigen. It is made by normal prostate cells as well as abnormal cells. Most PSA is released into semen, while a smaller amount circulates in the blood. A PSA result is generally reported in nanograms per milliliter (ng/mL).
Although PSA is often discussed in connection with prostate cancer, it is better understood as a marker of prostate activity. Prostate cancer may raise PSA, but so can BPH, prostatitis, urinary infection, urinary retention, and recent irritation or manipulation of the prostate.[1]
| Testing context | Question being asked | Important limitation |
|---|---|---|
| Screening without symptoms | Would an informed screening result justify additional risk assessment? | Screening has potential benefits and harms and is not automatically appropriate for every person or every year. |
| Evaluation of symptoms or an abnormal examination | Could prostate activity be contributing to the clinical picture? | PSA cannot identify the cause of urinary or pelvic symptoms and does not replace examination, urine testing, imaging, or other evaluation. |
| Monitoring a known prostate condition | Is the PSA stable or changing in a way that deserves review? | The reason for monitoring, treatment, medications, and assay method affect interpretation. |
| Monitoring after prostate-cancer treatment | Is PSA remaining at the expected post-treatment level or showing a confirmed trend? | Post-treatment values must not be interpreted using general screening ranges. |
There is no universal PSA cutoff that separates cancer from noncancer. Historically, 4.0 ng/mL has often been used as a decision point, but some clinicians use lower or higher thresholds depending on age, risk, medications, prostate size, previous results, and the purpose of testing. Cancer can occur below 4.0 ng/mL, while benign conditions can produce results well above it.[1]
| PSA result | General context | Possible next discussion |
|---|---|---|
| Below 2.5 ng/mL | Often associated with lower immediate concern in a screening context, but it does not exclude prostate cancer. | Consider age, health, risk, baseline, and an appropriate future screening interval. |
| 2.5-4.0 ng/mL | May be acceptable in one situation and more concerning in another. Some organizations use 2.5 ng/mL when discussing screening intervals. | Review prior results, risk factors, medications, symptoms, and the reason for testing. |
| 4.0-10.0 ng/mL | Often called a borderline or gray range. Prostate cancer is one possible explanation, but benign enlargement and inflammation are common alternatives. | Confirmation, clinical evaluation, percent-free PSA, risk assessment, imaging, or urology referral may be considered. |
| Above 10.0 ng/mL | Usually creates greater concern than a mildly elevated result, but it still cannot identify the cause, cancer grade, or stage. | Timely professional evaluation and confirmation are generally appropriate. |
| Any unexpected rise | May reflect biological variation, preparation, inflammation, infection, medication effects, a recent procedure, or a meaningful change. | Review temporary influences and determine whether and when confirmation is appropriate. |
No single number is dangerous for everyone. Concern generally rises as PSA rises, but the number alone cannot show whether cancer is present, whether a cancer would be clinically significant, or whether treatment is needed. A substantially elevated or rapidly changing result deserves timely review, especially when accompanied by symptoms or an abnormal examination, but it should be treated as a signal for evaluation rather than a diagnosis.
Age can influence PSA because the prostate often enlarges over time, but fixed age-based normal ranges can create false reassurance or unnecessary anxiety. Screening decisions should also consider overall health, expected longevity, family history, ancestry, inherited cancer risk, earlier PSA values, and personal preferences.
| Organization | Patient-facing summary | Important context |
|---|---|---|
| American Urological Association/Society of Urologic Oncology | The 2026 amendment supports personalized screening and rescreening decisions and updates the role of medications, biomarkers, MRI, and biopsy techniques. | Apply the full guideline in a clinician-patient discussion rather than using one age or cutoff for everyone.[2] |
| American Cancer Society | Discuss screening at age 50 for average-risk men expected to live at least 10 more years; age 45 for higher-risk men; and age 40 for those at still higher familial risk. | These are ages for an informed discussion, not universal testing mandates or age-specific normal PSA ranges.[3] |
| U.S. Preventive Services Task Force | The current final recommendation supports an individual decision for men ages 55-69 and recommends against routine PSA-based screening at age 70 or older. | This recommendation applies to asymptomatic screening; symptom evaluation and post-treatment monitoring are different situations.[4] |
Guidelines differ because they weigh benefits, false positives, biopsy harms, overdiagnosis, overtreatment, age, risk, and life expectancy differently. The appropriate question is not simply, "Am I old enough for a PSA?" It is, "Would knowing this result improve a decision that matters to me?"
| Factor | Possible effect | What to discuss before interpreting the result |
|---|---|---|
| Benign prostatic hyperplasia (BPH) | More benign prostate tissue can produce more PSA. | Urinary symptoms, prostate size, prior PSA values, and clinical examination. |
| Prostatitis or urinary infection | Inflammation may cause a temporary, sometimes substantial, PSA increase. | Fever, chills, painful urination, pelvic discomfort, urgency, recent infection, and appropriate urine testing. |
| Ejaculation | May temporarily raise PSA. | Whether ejaculation occurred during the two days before collection.[1] |
| Cycling or vigorous lower-body activity | May transiently increase PSA in some people. | Activity during the two days before the test and whether repeat testing under consistent conditions is appropriate. |
| Recent catheterization, biopsy, surgery, or prostate procedure | Prostate manipulation can temporarily raise PSA; the effect may last longer after biopsy. | The procedure type, date, and clinician-recommended waiting period. |
| Urinary retention | Acute retention or obstruction may affect PSA and requires clinical evaluation. | Difficulty emptying the bladder, pain, and whether urgent care is needed. |
| Prostate cancer | Cancer may increase PSA, but some prostate cancers produce little PSA. | Overall risk, examination, repeat result, secondary testing, imaging, and whether tissue evaluation is appropriate. |
| Finasteride, dutasteride, and other therapies | Some medications can lower measured PSA and change the threshold used for follow-up. | Medication name, dose, duration, adherence, and the interpreting clinician's adjustment. Do not stop medication for testing unless the prescriber instructs you to do so. |
Early prostate cancer often causes no symptoms. Urinary symptoms are common and are frequently caused by BPH, prostatitis, infection, bladder disorders, diabetes, or other noncancerous conditions. Symptoms alone cannot identify the cause.
| Scenario | What it may reflect | Testing that may add information | Nonlaboratory follow-up |
|---|---|---|---|
| Informed screening without symptoms | Age- and risk-related screening decision | PSA Total Test | Shared decision-making about benefits, harms, and follow-up. |
| Unexpectedly elevated PSA without concerning symptoms | Biological variation, preparation, BPH, inflammation, medication effect, or cancer risk | Repeat PSA Total Test; selected use of the PSA Free and Total Test | Medication review, examination, risk calculation, imaging, or urology referral as appropriate. |
| Weak stream, urgency, frequency, or nighttime urination | BPH, obstruction, bladder condition, infection, inflammation, diabetes, or another cause | PSA Total Test when clinically relevant; Urinalysis Complete Test for selected urinary questions | History, physical examination, medication review, and possible urologic evaluation. |
| Burning urination, fever, chills, or pelvic pain | Urinary infection or acute prostatitis, among other causes | Urinalysis Complete Test and Culture, Urine, Routine Test when professionally appropriate | Prompt medical evaluation; do not rely on routine PSA testing alone. |
| History of prostatectomy for prostate cancer | Specialist-directed treatment monitoring | Post-Prostatectomy PSA Test | Use the monitoring schedule and interpretation established by the treating urology or oncology team. |
| PSA testing may help | PSA testing cannot establish by itself |
|---|---|
| Measure the amount of PSA circulating in blood | Whether prostate cancer is present |
| Support an informed screening decision | The cause of an elevated result |
| Show whether a result is stable, fluctuating, rising, or falling | The location, grade, stage, or clinical significance of a tumor |
| Contribute to evaluation of selected prostate or urinary concerns | Whether a biopsy is necessary without the rest of the risk assessment |
| Support monitoring after a prostate-cancer diagnosis or treatment | Whether treatment should begin, stop, or change |
The right test depends on the question. A larger group of tests is not automatically better, and urinary testing should not be added to an elevated PSA unless symptoms or history provide a reason.
| Test | Use status | What it measures | When it may add information | Major limitation |
|---|---|---|---|---|
| PSA Total Test | Risk-based or targeted; monitoring | Total circulating PSA, including free and protein-bound forms | Informed screening, selected prostate concerns, confirmation, or clinician-directed monitoring | Cannot diagnose cancer or identify why PSA is elevated. |
| PSA Free and Total Test | Risk-based or targeted | Total PSA, free PSA, and the calculated percent-free PSA | May add context when total PSA is elevated or in a borderline range | Does not diagnose cancer or serve as a stand-alone biopsy rule. |
| Post-Prostatectomy PSA Test | Specialist-directed monitoring | Very low PSA concentrations after surgical removal of the prostate | Monitoring after prostatectomy according to an oncology or urology plan | Not intended for routine screening in someone with an intact prostate. |
| Urinalysis Complete Test | Risk-based or targeted | Physical, chemical, and microscopic urine findings | Selected urinary symptoms, blood, inflammation, or infection-related questions | Does not explain a PSA elevation or diagnose prostate cancer. |
| Culture, Urine, Routine Test | Risk-based or targeted | Growth and identification of bacteria or yeast in urine | Suspected urinary infection when symptoms and clinical context support culturing | A negative result does not exclude every cause of prostatitis or urinary symptoms. |
Some PSA circulates unattached, or free, while the rest is attached to blood proteins. Percent-free PSA compares free PSA with total PSA. In selected people with a borderline total result, a lower percentage is generally associated with greater prostate-cancer concern and a higher percentage may be more consistent with a benign cause. There is no universally correct percentage that determines whether someone should have imaging or a biopsy; the result belongs in a broader risk assessment.[5]
For a more focused explanation, see how free PSA, total PSA, and percent-free PSA differ.
Educational framework - not a diagnostic or treatment algorithm.
A falling repeat value may support a temporary explanation, while persistent elevation deserves review. Neither pattern should be interpreted without the surrounding clinical information.
| Factor | General guidance | Important caution |
|---|---|---|
| Fasting | Fasting is generally not required when PSA is the only test. | Other tests in the same order may require fasting; follow every order-specific instruction. |
| Ejaculation | Avoid ejaculation for about two days before collection when practical.[1] | If this was not possible, record the timing rather than assuming the result is invalid. |
| Cycling or vigorous exercise | Avoid vigorous cycling or activity likely to irritate the prostate for about two days before testing when practical. | Routine activity does not automatically invalidate a result; context matters. |
| Illness or urinary symptoms | Tell the interpreting professional about fever, painful urination, pelvic pain, infection, or retention. | Do not delay urgent evaluation merely to obtain a cleaner PSA baseline. |
| Recent prostate or urinary procedure | Ask how long to wait after biopsy, catheterization, surgery, or another procedure. | The appropriate interval depends on the procedure and clinical purpose. |
| Medications and supplements | Provide a complete list, especially finasteride, dutasteride, hormone therapy, and medications used for prostate conditions. | Do not stop or change a medication unless the prescribing professional instructs you to do so. |
| Laboratory consistency | When monitoring a trend, using the same laboratory and assay can improve comparability. | A method change can make two numbers less directly comparable. |
Start with the reason for testing rather than the flag alone. A laboratory reference interval describes how that laboratory reports the assay; it is not automatically the same as a screening cutoff, biopsy threshold, treatment target, or post-treatment monitoring threshold. For a fuller explanation, review how reference intervals, flags, units, variation, and trends should be read.
| Term | What it means | PSA caution |
|---|---|---|
| Laboratory reference interval | The range or limit supplied with the laboratory report for that method. | A value inside the interval does not guarantee that cancer is absent. |
| Screening decision point | A value used with age, risk, preferences, and evidence to decide whether more assessment may be appropriate. | Different organizations and clinical settings may use different values. |
| Monitoring target | A value or pattern defined for a known condition or treatment plan. | Post-treatment targets are not interchangeable with screening thresholds. |
| Trend | A sequence of comparable results over time. | PSA velocity should not be used by itself to determine imaging, biopsy, or treatment. |
Seek prompt medical evaluation for complete inability to urinate, fever and chills with painful or frequent urination, visible blood in urine, severe lower-abdominal or urinary-tract pain, severe pelvic or back pain, weakness, unexplained weight loss, or other sudden or concerning symptoms.[7]
Ulta Lab Tests allows eligible patients to review available laboratory tests online, see the listed price before ordering, follow the collection instructions for the selected test, and receive results through an online account. Direct access can support a more informed conversation, but it does not replace a clinician, urologist, examination, imaging, or biopsy.
Before choosing a test, use the guide to direct-access lab testing, preparation, collection, results, and follow-up. Unexpected or changing PSA results should be reviewed with a qualified healthcare professional.
There is no PSA value that is universally normal for every person. A value below 4.0 ng/mL has historically been viewed as less concerning, but prostate cancer can occur below that value and benign conditions can produce higher results. Age, prostate size, medications, symptoms, risk factors, prior results, laboratory method, and the purpose of testing all matter.
No. High PSA levels may occur with prostate cancer, BPH, prostatitis, urinary infection, retention, ejaculation, cycling, or a recent prostate procedure. A high result identifies a reason to review the context and consider follow-up; it does not diagnose cancer. A biopsy may be needed when tissue is required to determine whether cancer is present.
There is no single dangerous level. Higher values generally create more concern, and a result above 10 ng/mL usually warrants timely professional evaluation, but even a substantially elevated PSA cannot reveal the cause, grade, or stage by itself. Symptoms, confirmation, medications, earlier results, risk factors, examination, imaging, and specialist assessment determine the next step.
Yes. A PSA below 4.0 ng/mL lowers concern in many screening situations but does not guarantee that prostate cancer is absent. Persistent symptoms, an abnormal examination, a strong family history, inherited risk, or a meaningful change from a previous baseline may still justify professional evaluation.
A newly elevated screening PSA is often confirmed before secondary biomarkers, imaging, or biopsy, particularly when the person has no urgent symptoms. The NCI describes repeat testing in approximately six to eight weeks, although infection, inflammation, recent procedures, medications, and the degree of elevation can change the timing.[1]
Total PSA includes both protein-bound and unbound PSA. The PSA Free and Total Test reports both forms and calculates percent-free PSA. In selected people with a borderline total result, the percentage may refine risk assessment, but it cannot diagnose cancer or determine by itself whether imaging or biopsy is needed.
Yes. Ejaculation and vigorous cycling can transiently increase PSA in some people. The NCI recommends avoiding activities that may raise PSA for two days before testing when practical. If they occurred, record the timing and discuss whether the result should be repeated under more consistent conditions rather than assuming that it is valid or invalid.
Fasting is generally not needed when PSA is the only test. It may be required when other tests in the order have fasting instructions. Review every test's preparation requirements, and do not assume that a panel follows the instructions for only one component.
Yes. Finasteride and dutasteride can lower measured PSA and change how a result is interpreted. Other therapies may also affect PSA. Provide the interpreting professional with a complete medication and supplement list, including the dose and duration when known. Do not stop or change a medicine unless the prescribing professional tells you to do so.
There is no single interval for everyone. Frequency depends on why testing is being done, age, baseline PSA, prior trends, ancestry, family history, overall health, expected longevity, treatment history, and personal preferences. Screening intervals and post-treatment monitoring schedules are not interchangeable.
Ulta Lab Tests offers direct access to the PSA Total Test and selected related tests where available. Direct ordering can provide objective information, but it does not replace an informed screening discussion, professional interpretation, or follow-up for an abnormal or changing result.
A healthcare professional may review temporary influences and medications, compare prior results, repeat the PSA, evaluate urinary symptoms, perform an examination, use a risk calculator, consider percent-free PSA or another biomarker, request prostate MRI, or refer to a urologist. Biopsy may be considered when tissue is required to determine whether cancer is present.
PSA levels are most useful when they answer a defined question and are interpreted with preparation, symptoms, medications, previous results, age, prostate size, family history, inherited risk, and overall health. A high PSA is not a cancer diagnosis, and a low PSA is not an absolute guarantee.
Use focused testing, confirm unexpected findings when appropriate, and involve a qualified healthcare professional when results change or symptoms are present. Explore the Men's Health Blood Tests pillar, learn how to interpret laboratory values and trends, and review the direct-access testing process before deciding what to do next.
This content is educational and does not provide individual diagnosis or treatment. Laboratory testing does not replace medical history, examination, imaging, biopsy, specialist evaluation, or emergency care. Review unexpected, changing, or abnormal results with a qualified healthcare professional.
Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.
Originally published: July 13, 2026 | Updated: September 1 2026
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
